Thermo Fisher’s clinical research subsidiary, PPD, invests $59 million in sample management and testing capacity for vaccines and cell and gene therapy products with its expansion of laboratory operations in Kentucky.
A ‘significant shift’ is under way in global outsourcing strategies: with the sector moving away from phase-appropriate development in favor of a more forward-looking model – with experts advising starting the search for an outsourcing partner as early...
Updated interim results from Part A the RINGSIDE pivotal Phase 2/3 study of the company’s AL102 new drug showed consistent early tumor shrinkage with measures deepening over time, plus good tolerability at all doses.
Sanofi has teamed up with TrialSpark to jointly acquire and advance clinical-stage candidates, leaning on its partner’s tech-enabled drug development capabilities to hustle the programs toward approval.
The company, through its subsidiary, PPD, announced that it had created a network that would provide learning materials to those investigators and research sites looking to use decentralized clinical trials (DCTs) for drug development.
TransCelerate BioPharma continues to work towards “bringing new medicines to patients faster”. We caught up with the organization’s CEO to hear about its main achievements over the past decade and learn about what comes next.
Outsourcing-Pharma caught up with Esther Mahillo, VP of Operational Strategy and Feasibility, Precision for Medicine to talk about advancements in patient enrollment in oncology and rare disease clinical trials.
Epic’s Life Sciences program is released with the aim to connect providers, pharmaceutical companies, and medical device manufacturers to recruit research participants, expand clinical trial access, and to speed up therapy development.
Autoimmune diagnostics life sciences company Exagen is heralding the completion of the CAPSTONE study as evidence that its AVISE Lupus test is more clinically effective than traditional ANA methods (tANA), benefiting patients, providers and payers by...
The trial for Renovia’s leva Pelvic Health System used ObvioHealth’s platform to deliver real-time data while their virtual site team engaged with the patients via the app, resulting in a 94.5% compliance rate.